We found that one-third of human sebaceous tumors examined had double-nucleotide substitutions in the same LEF1 allele, irrespective of DNA mismatch repair status. The mutations impaired both LEF1 binding to β-catenin and transcriptional activation, and are the first tumor-associated mutations that inactivate Wnt signaling. Mutant LEF1 not only inhibited expression of β-catenin target genes but also stimulated expression of sebocyte markers, suggesting that it may determine the differentiated characteristics of sebaceous tumors.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Stem Cell Reviews and Reports Open Access 10 February 2022
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Reya, T. & Clevers, H. Nature 434, 843–850 (2005).
Vogelstein, B. & Kinzler, K.W. Nat. Med. 10, 789–799 (2004).
Alonso, L. & Fuchs, E. Genes Dev. 17, 1189–1200 (2003).
Chan, E., Gat, U., McNiff, J.M. & Fuchs, E. Nat. Genet. 21, 410–413 (1999).
Niemann, C., Owens, D.M., Hülsken, J., Birchmeier, W. & Watt, F.M. Development 129, 95–109 (2002).
Troy, J.L. & Ackerman, A.B. Am. J. Dermatopathol. 6, 7–13 (1984).
Kruse, R. et al. J. Invest. Dermatol. 116, 463–465 (2001).
Niemann, C. et al. Proc. Natl. Acad. Sci. USA 100 Suppl. 1, 11873–11880 (2003).
van den Brink, G.R. et al. Nat. Genet. 36, 277–282 (2004).
Ross, S.E. et al. Science 289, 950–953 (2000).
Liu, J. & Farmer, S.R. J. Biol. Chem. 279, 45020–45027 (2004).
Ikehata, H., Kudo, H., Masuda, T. & Ono, T. Mutagenesis 18, 511–519 (2003).
Queille, S. et al. Mol. Carcinog. 22, 167–174 (1998).
Silva-Vargas, V. et al. Dev. Cell 9, 121–131 (2005).
Owens, D.M. & Watt, F.M. Nat. Rev. Cancer 3, 444–451 (2003).
We are grateful to the Cancer Research UK (CR-UK) Equipment Park staff for technical assistance with sequencing. We thank P. Bates and B. Ponder for comments, and M. van de Wetering and C. Lo Celso for reagents. This work was supported by CR-UK (to H.T., I.S. and F.M.W.), US National Institutes of Health grant AR02179 (to S.L.), Harvard Skin Disease Research Center grant P30AR042689 (to A.J.F.L.) and a Uehara Memorial Foundation Fellowship (to H.T.). C.C.Z.'s contribution to this work was to provide SZ95 cells; he is a co-author under the terms of a Materials Transfer Agreement with F.M.W.
Christos C. Zouboulis is the owner of the patents 'Sebocytes, sebocyte cell line and uses thereof' EP1151082, DE19903920, AU200019804, and has filed patent applications US2002034820, CA2360762, CN1344314T, JP2002535984, IL144683D, PL350191, HU0200048 (international patent priority WO0046353 of 15.12.1999). The other authors declare that they have no competing financial interests.
Expression of mismatch repair enzymes in human sebaceous tumours. (PDF 8952 kb)
Groucho/TLE expression and interaction with LEF1. (PDF 11345 kb)
Expression of p53 and MMP7 in human SCC and sebaceous tumours. (PDF 20299 kb)
Panel of sebaceous tumours examined. (PDF 37 kb)
About this article
Cite this article
Takeda, H., Lyle, S., Lazar, A. et al. Human sebaceous tumors harbor inactivating mutations in LEF1. Nat Med 12, 395–397 (2006). https://doi.org/10.1038/nm1386
This article is cited by
Stem Cell Reviews and Reports (2022)